Eli Lilly and Co.

Appeals court rejects Lilly over Gemzar patent

November 1, 2010
 IBJ Staff and Bloomberg News
Without an appeal, generic drugs are now poised to wipe away most of Lilly's $750 million in annual U.S. revenue from Gemzar.
More

Indiana's life sciences industry sees trouble ahead

October 30, 2010
Associated Press
Indiana's life sciences industry has weathered the recession relatively well, but Eli Lilly's struggles and tight capital markets could threaten the future.
More

BioCrossroads helping laid-off life sciences workers land safely

October 30, 2010
Chris O'Malley
Indiana firms have dismissed more than 1,400 life science workers over the last two years. Now BioCrossroads has launched a website that aims to keep that talent in the state.
More

Eli Lilly will have to beat odds to meet drug-rollout goals

October 30, 2010
J.K. Wall
Eli Lilly and Co. executives have said repeatedly that the company’s bulging pipeline will produce two new drugs per year, beginning in 2013. But only three times in the past six decades has Lilly been able to launch two or more new drugs in back-to-back years.
More

Indianapolis-area experts see bright spots amid ongoing real estate weaknessRestricted Content

October 23, 2010
Health care shows signs of life, and multi-family buildings continue to hold their own, experts said during a recent IBJ Power Breakfast.
More

Analysts: Lilly setbacks might spur shopping spree

October 22, 2010
Bloomberg News
CEO John Lechleiter claims Eli Lilly and Co. isn't interested in big acquisitions to bolster its flagging drug pipeline, but its recently devalued partner Amylin Pharmaceuticals might be the right fit, industry analysts say.
More

Analysts grill Lilly execs on strategy after setbacks

October 21, 2010
J.K. Wall
Wall Street analysts on Thursday demanded to know what new things Eli Lilly and Co. is planning since the company’s vaunted pipeline has failed to produce a drug that will boost revenue after a wave of patent expirations. The answer: Not much.
More

Lilly raises forecast after beating third-quarter profit estimates

October 21, 2010
J.K. Wall
The Indianapolis-based drugmaker reported a profit of $1.3 billion in the quarter ended Sept. 30, up 38 percent compared with last year. Excluding extraordinary items from a year ago, Lilly’s profit was up 2 percent.
More

Lilly suspends clinical trials after diabetes treatment fails

October 20, 2010
Bloomberg News
Eli Lilly and Co. and its development partner said an experimental diabetes treatment failed to help patients in a late-stage study, the second setback for a Lilly diabetes drug candidate in two days.
More

UPDATE: Lilly, others see stock slide after drug rejection

October 20, 2010
Bloomberg News
Stock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.
More

Some Lilly-paid docs sport spotty records

October 20, 2010
J.K. Wall
Eli Lilly and Co. paid more than $102 million last year and early this year to physicians for talking up Lilly drugs to other doctors. Yet 88 of the doctors Lilly pays have been sanctioned by state medical boards.
More

FDA demands more tests on new Lilly diabetes drug

October 19, 2010
J.K. Wall
Eli Lilly and Co. will have to wait at least 18 months and conduct more studies before it wins market approval of a once-weekly version of diabetes drug Byetta, a potential billion-dollar drug.
More

Lilly to close drug discovery center in Singapore

October 18, 2010
Bloomberg News
Indianapolis-based Eli Lilly and Co. will close its drug discovery center in Singapore, three years into a five-year, $150 million plan to expand it.
More

Lilly falls short on 'field goal' attempt

October 13, 2010
J.K. Wall
Eli Lilly and Co.’s “miss” on a new use for its cancer drug Alimta was a rare failure to get an existing drug approved for a new use—even though the company has struggled mightily to get entirely new drugs to market.
More

Lilly's Erbitux shows mixed results in cancer studies

October 11, 2010
Bloomberg News
In combination with chemotherapy, the drug failed to help colon-cancer patients in a European trial but did delay the spread of breast cancer in some patients with a certain type of aggressive tumor.
More

Coordinating Lilly 'Day of Service' a major undertaking

October 7, 2010
Scott Olson
Getting 8,500 volunteers to where they're supposed to be along Interstate 70 relies on a system of color-coded passes. By 6 p.m. Thursday, they'll have planted 1,600 trees and 72,000 shrubs and perennials (with photo gallery).
More

Consultants: Pharma industry facing huge changes

October 6, 2010
J.K. Wall
Heitzman_WatchVideoTo date, most analysts say health reform turned out pretty well for the pharmaceutical industry. But a detailed analysis by Deloitte Consulting says the indirect effects of reform will deliver a gut punch to the industry that will lead to full-scale transformation akin to what the telecommunications world has seen over the past three decades.
More

Drugmakers’ ‘doughnut hole’ deal to shave sales

October 1, 2010
Bloomberg News
Drugmakers including Pfizer Inc., AstraZeneca, Bristol-Myers Squibb Co. and Eli Lilly and Co. may provide more than $2 billion in drug discounts to senior citizens next year under a deal pharmaceutical companies made with the White House.
More

Lilly sues drug distributor over generic Zyprexa sales

September 29, 2010
Bloomberg News
Celesio's Lloyds Pharmacy and Aah Pharmaceuticals businesses sold about 800,000 tablets of generic Zyprexa before agreeing in 2008 to halt sales, Lilly said in a complaint filed in the High Court in London.
More

$150M 'North of South' project moving ahead

September 27, 2010
 IBJ Staff
Officials are announcing details of an ambitious downtown development planned for 10 acres Eli Lilly and Co. owns near its Indianapolis headquarters. The project will include a hotel, apartments, restaurants and retail space and a YMCA.
More

Lilly discovers social media

September 22, 2010
J.K. Wall
Eli Lilly and Co. launched its own blog this month, dubbed LillyPad, to try to start discussions about public policy and corporate social responsibility. The Indianapolis-based drugmaker also launched an accompanying Twitter feed.
More

Lilly wins reversal of class action in Zyprexa suit

September 10, 2010
Bloomberg News
A U.S. appeals court in New York threw out a September 2008 ruling that said plaintiffs could pursue as a group claims that Zyprexa marketing caused them to pay more for the drug than what it was worth. The plaintiffs were seeking $6.8 billion in damages.
More

Lilly investing up to $150M in VC funds

September 8, 2010
Bloomberg News
The three venture funds, which will focus on drug development, may be worth a total of $750 million, up to $250 million each, and Lilly will contribute as much as 20 percent of the money.
More

Lab used by Lilly, peers accused of animal cruelty

September 8, 2010
 IBJ Staff and Associated Press
An investigation found that lab employees kicked, threw, and dragged dogs; lifted rabbits by their ears and puppies by their throats; violently slammed cats into cages; and exposed animals to toxic chemicals.
More

CEO says Lilly still not interested in huge acquisitions

September 7, 2010
 IBJ Staff and Bloomberg News
Lilly remains disinterested in making big acquisitions and aims to rely on the company’s own pipeline, CEO John Lechleiter said Tuesday, re-emphasizing a strategy he has outlined several times in the past year.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. You are correct that Obamacare requires health insurance policies to include richer benefits and protects patients who get sick. That's what I was getting at when I wrote above, "That’s because Obamacare required insurers to take all customers, regardless of their health status, and also established a floor on how skimpy the benefits paid for by health plans could be." I think it's vital to know exactly how much the essential health benefits are costing over previous policies. Unless we know the cost of the law, we can't do a cost-benefit analysis. Taxes were raised in order to offset a 31% rise in health insurance premiums, an increase that paid for richer benefits. Are those richer benefits worth that much or not? That's the question we need to answer. This study at least gets us started on doing so.

  2. *5 employees per floor. Either way its ridiculous.

  3. Jim, thanks for always ready my stuff and providing thoughtful comments. I am sure that someone more familiar with research design and methods could take issue with Kowalski's study. I thought it was of considerable value, however, because so far we have been crediting Obamacare for all the gains in coverage and all price increases, neither of which is entirely fair. This is at least a rigorous attempt to sort things out. Maybe a quixotic attempt, but it's one of the first ones I've seen try to do it in a sophisticated way.

  4. In addition to rewriting history, the paper (or at least your summary of it) ignores that Obamacare policies now must provide "essential health benefits". Maybe Mr Wall has always been insured in a group plan but even group plans had holes you could drive a truck through, like the Colts defensive line last night. Individual plans were even worse. So, when you come up with a study that factors that in, let me know, otherwise the numbers are garbage.

  5. You guys are absolutely right: Cummins should build a massive 80-story high rise, and give each employee 5 floors. Or, I suppose they could always rent out the top floors if they wanted, since downtown office space is bursting at the seams (http://www.ibj.com/article?articleId=49481).

ADVERTISEMENT